文献速递甲状腺疾病

甲状腺眼病治疗的未来展望

Future Projections in Thyroid Eye Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本文综述了甲状腺眼病(TED)的当前和新兴治疗,基于对发病机制的新认识。检索PubMed相关文献,分析转化研究和临床试验。手术用于慢性TED康复或紧急压迫性视神经病变;糖皮质激素疗效不一且副作用显著;非甾体免疫抑制剂益处有限;利妥昔单抗、托珠单抗等单克隆抗体对TED失活有效;替妥木单抗(IGF-1R抑制剂)在活动性TED中显著改善突眼、临床活动度评分、复视和生活质量,耐受性良好;其他新疗法处于临床前和临床试验阶段。

要点

  • 手术仅用于慢性TED康复或紧急压迫性视神经病变。
  • 糖皮质激素疗效不一且可能暂时,副作用显著。
  • 替妥木单抗在活动性TED中显著改善突眼、临床活动度评分、复视和生活质量,耐受性良好。

核心结论

  • 对TED分子机制的新认识(尽管不完整)带来了有前景的新疗法,并改善了TED患者的结局。
  • 这些新疗法的完整作用及其与传统免疫抑制的关系应在未来几年内阐明。

研究设计与样本

  • 本综述检索并分析了PubMed上关于TED治疗的近期转化研究和临床试验的同行评议文献,检索词为“thyroid eye disease”、“Graves' ophthalmopathy”、“thyroid orbitopathy”和“Graves' orbitopathy”。

主要发现

  • 手术保留用于慢性TED的康复或紧急压迫性视神经病变。
  • 口服和静脉糖皮质激素治疗已使用数十年,在急性TED中疗效不一,但结果可能暂时且副作用显著。
  • 非甾体口服免疫抑制剂在TED中提供适度益处。
  • 包括利妥昔单抗和托珠单抗在内的几种免疫调节单克隆抗体已显示可使TED失活。
  • 替妥木单抗(一种胰岛素样生长因子1受体(IGF-1R)抑制剂)在活动性TED患者中已显示突眼、临床活动度评分、复视和生活质量显著改善,且耐受性良好。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This review aims to summarize current and emerging therapies for treatment of thyroid eye disease (TED), in the light of novel understanding of pathogenetic mechanisms, leading to new treatment options and clinical trials. METHODS: We reviewed and analyzed peer-reviewed literature reporting recent translational studies and clinical trials in the treatment of TED. Searches were made at www.pubmed.gov with keywords "thyroid eye disease," "Graves' ophthalmopathy," "thyroid orbitopathy," and "Graves' orbitopathy." RESULTS: Surgery is reserved for rehabilitation in chronic TED or for emergent compressive optic neuropathy. Oral and intravenous glucocorticoid therapy has been used for decades with variable efficacy in acute TED, but results may be temporary and side effects significant. Nonsteroidal oral immunosuppressive agents offer modest benefit in TED. Several immunomodulatory monoclonal antibodies, including rituximab and tocilizumab, have shown efficacy for inactivating TED. Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, clinical activity score, diplopia, and quality of life in patients with active TED, with good tolerability. Newly proposed TED therapies, currently in preclinical and clinical trial phases, include thyroid-stimulating hormone (TSH) receptor inhibitory drugs, RVT-1401, local anti-vascular endothelial growth factor therapy, IGF-1R drugs delivered subcutaneously and orally, and desensitization to the TSH receptor with modified TSH receptor peptides. CONCLUSION: New, albeit incomplete, understanding of the molecular mechanisms of TED has led to new promising therapies and offered improved outcomes in TED patients. Their full role and their relationship to classical immune suppression should be clarified over the next few years.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barbesino G, Salvi M, Freitag SK, et al. Future Projections in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022. PMID: 36346684. doi:10.1210/clinem/dgac252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。